This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitagawa, H.
Right arrow Articles by Kato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitagawa, H.
Right arrow Articles by Kato, S.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, June 2002, p. 3698-3706, Vol. 22, No. 11
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.11.3698-3706.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Ligand-Selective Potentiation of Rat Mineralocorticoid Receptor Activation Function 1 by a CBP-Containing Histone Acetyltransferase Complex

Hirochika Kitagawa,1,2 Junn Yanagisawa,1,3 Hiroaki Fuse,4 Satoko Ogawa,1 Yoshiko Yogiashi,1,3 Atsuro Okuno,5 Hiromichi Nagasawa,5 Toshihiro Nakajima,6 Toshio Matsumoto,2 and Shigeaki Kato1,3*

Institute of Molecular and Cellular Biosciences,1 Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, Bunkyo-ku,5 Pharmacological Research Department, Teikoku Hormone Manufacturing Company, Ltd., Tokyo,4 First Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima,2 CREST, Japan Science and Technology, Kawaguchi, Saitama,3 Institute of Medical Science, St. Marianna University School of Medicine, Miyamae-ku, Kawasaki, Japan6

Received 16 November 2001/ Returned for modification 31 January 2002/ Accepted 21 February 2002


arrow
ABSTRACT
 
The rat mineralocorticoid receptor (MR) has two activation functions in distinct regions of the A/B domain, designated activation function 1a (AF-1a; amino acids 1 to 169) and AF-1b (amino acids 451 to 600). Since the p160 family protein TIF2, a known component of the AF-2 coactivator complex, potentiates the transactivation function of AF-1b but not that of AF-1a, it is likely that some other, novel protein complex interacts with the AF-1a region. Therefore, we attempted to identify such coactivator complexes from HeLa nuclear extracts by biochemical purification using a glutathione S-transferase-MR AF-1a fusion protein. Purified AF-1a region-interacting proteins were found to contain RNA helicase A (RHA) and CBP. Further analysis showed that RHA interacted with the AF-1a region directly and then recruited a complex with histone acetyltransferase (HAT) activity that contained CBP. For full-length MR, aldosterone, but not hydrocortisone, was found to induce the binding of RHA/CBP complexes to the AF-1a region, as well as to allow the cooperative potentiation of MR transcriptional activity by RHA and CBP. In addition, a chromatin immunoprecipitation assay showed that aldosterone-bound MR, but not hydrocortisone-bound MR, recruited RHA/CBP complexes to native MR target gene promoters. Our results suggested that an altered conformation of the A/B region induced by aldosterone, but not hydrocortisone, might determine the accessibility of MR AF-1a to RHA/CBP complexes.


arrow
INTRODUCTION
 
Mineralocorticoid receptor (MR) is a member of the steroid/thyroid hormone nuclear receptor superfamily and acts as a ligand-inducible transcription factor responsible for ion homeostasis by regulating ion channel expression in epithelial cells (1, 5, 11, 14). Recently, it was shown that MR participates in a wide range of biological functions in nonepithelial tissues, including the heart and brain (5, 17, 32). MR has two native ligands, aldosterone (mineralocorticoid) and hydrocortisone (glucocorticoid), both of which bind MR and induce its transactivational function (26). However, the ligands mediate distinct physiological actions via MR (10, 20, 21, 40, 58). While these different physiological actions may partially depend on the enzymatic activity of 11ß-hydroxysteroid dehydrogenase type 2 (11ßHSD2), which inactivates hydrocortisone (glucocorticoid) and results in the preferential activation of MR by aldosterone in target tissues (15), this does not explain the distinct physiological actions of the two hormones in nonepithelial cells, where 11ßHSD is not present (13, 34).

Nuclear receptors have two functional domains in their N-terminal A/B and C-terminal E/F domains. While autonomous activation function 2 (AF-2) in the C-terminal E/F domain is ligand binding dependent (49), autonomous activation function 1 (AF-1) in the N-terminal A/B domain is constitutively active, and unliganded nuclear receptors are able to block the transactivational function of AF-1 (31). Compared with the well-conserved E/F domains, the A/B domains, which contain AF-1, display no regions that are highly conserved between different nuclear receptors. We have previously detected two transactivational functions in MR, AF-1a and AF-1b, in the N-terminal A/B domain (16). Although previous studies have suggested a possible role for the A/B domain in ligand-selective functions of MR (26, 61), the physiological role of the A/B domain at the molecular level remains unclear.

DNA binding activators, like nuclear receptors, require basic transcription factors and coactivators for RNA polymerase II-mediated gene activation. RNA helicase A (RHA) is reported to be one of the components of the RNA polymerase II holoenzyme complex (36) and is a member of the DExH family of ATPase/helicases (48). Recent studies have shown that RHA interacts directly with coactivators and activators such as CBP/p300, BRCA1 (breast cancer-specific tumor suppressor protein), and SMN (survival motor neuron) to stabilize complex formation (2, 36, 39). These studies indicated that RHA might be a common coactivator acting as a bridging factor between basal transcription factors and activators.

For the ligand-induced transactivation function of nuclear receptors, two classes of coactivator complexes for AF-2 have been identified so far (11, 19). One is a histone acetyltransferase (HAT) complex thought to contain CBP/p300, p160 protein family members (SRC-1 [steroid receptor coactivator 1], TIF2 [transcriptional intermediate factor 2], AIB1 [amplified in breast and ovarian cancer protein 1]), and an RNA coactivator, SRA, along with other, unknown components (3, 30, 38, 50, 53). Histone acetylation by intrinsic HAT activity of complexes converts the nucleosome into a transcriptionally active state by facilitating the access of activators to DNA binding (37). The other AF-2 coactivator complex is the recently reported DRIP (vitamin D receptor-interacting protein)/TRAP (thyroid hormone receptor-associated protein) complex, which is composed of at least 12 proteins but has no HAT activity (23, 41, 42). Although these coactivator complexes are reported to interact directly with the A/B domains of some nuclear receptors (8, 25, 27, 54, 55), little is known regarding AF-1-specific coactivator complexes. For MR, our observations that AF-1b, but not AF-1a, activity was enhanced by p160-family proteins support the existence of novel coactivator complexes for AF-1a (16).

In this study we attempted to identify MR AF-1a-interacting complexes by biochemical purification and mass fingerprinting by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS). One of the purified AF-1a region-interacting protein complexes was found to contain RHA and CBP (referred to below as the RHA/CBP complex). The interaction between RHA/CBP complexes and AF-1a was mediated through direct binding of RHA to the AF-1a region of MR. The finding that RHA did not bind to any MR region except AF-1a supported our previous observation that RHA potentiated the transcriptional activity of AF-1a but not that of AF-1b. For full-length MR, recruitment of the RHA/CBP complex to the AF-1a region was induced by aldosterone rather than hydrocortisone, which suggested that binding of hydrocortisone to MR may make the MR AF-1a region inaccessible to the RHA/CBP complex. Our results also raised the possibility that the differences between the biological activities of aldosterone and hydrocortisone in target tissues may be due to the ligand-selective recruitment of RHA/CBP complexes to MR.


arrow
MATERIALS AND METHODS
 
Plasmids. Rat MR deletion mutants FLAG-MR, FLAG-AF-1a, FLAG-AF-1b, FLAG-AF-2, and pcDNA-TIF2 were constructed as previously described (16). A series of rat MR deletion fragments (consisting of amino acids 1 to 169, 170 to 450, or 451 to 600, or fragment DEF) were inserted in-frame into the pAcG 2T vector (Pharmingen), while the series of RHA deletion mutants (with amino acids 1 to 262, 255 to 664, 649 to 1077, or 1064 to 1270 deleted) and the resultant chimeric proteins fused to glutathione S-transferase (GST) were as described previously (12). MREx2-tk-Luc was constructed by inserting two mineralocorticoid-responsive elements (MREs) from the tyrosine aminotransferase gene promoter into the pGL3-Basic vector (Promega) with a thymidine kinase (TK) promoter which was described previously (52, 54). Human CBP cDNA was obtained as several fragments by PCR using HeLa cell cDNA as the template and was reconstructed into pcDNA3, as described previously (36).

Antibodies. Antibodies used were an anti-FLAG M2 monoclonal antibody (F3165; Sigma), an anti-hemagglutinin (anti-HA) antibody (no. 561; Medical and Biological Laboratories Co., Ltd.), an anti-CBP antibody (sc369; Santa Cruz Biotechnology), an anti-MR antibody (sc11412; Santa Cruz Biotechnology), and an anti-RHA antibody (as previously described [36]).

Purification and separation of MR AF1a-interacting proteins. HeLa nuclear extracts were loaded onto a P11 phosphocellulose column. After extensive washes with washing buffer (20 mM Tris-HCl [pH 7.9], 150 mM KCl, 0.2 mM EDTA, 0.05% NP-40, 10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM dithiothreitol [DTT]), bound proteins were eluted by using elution buffer (20 mM Tris-HCl [pH 7.9], 1 M KCl, 0.2 mM EDTA, 0.05% NP-40, 10% glycerol, 0.5 mM PMSF, 1 mM DTT) and were then dialyzed in GST-binding buffer (20 mM Tris-HCl [pH 7.9], 180 mM KCl, 0.2 mM EDTA, 0.05% NP-40, 0.5 mM PMSF, 1 mM DTT) containing bovine serum albumin (1 mg/ml). After 4 to 5 h of dialysis, immobilized GST-MR AF-1a fusion proteins on the beads were incubated at 4°C for 6 to 10 h with HeLa nuclear extracts. After three washes with GST wash buffer (GST-binding buffer with 0.1% NP-40), the beads were further washed with GST wash buffer containing 0.2% N-lauryl sarcosine (Sarkosyl; Sigma). Complexes bound to MR AF-1a were eluted with 15 mM reduced glutathione in elution buffer (50 mM Tris-HCl [pH 8.3], 150 mM KCl, 0.5 mM EDTA, 0.5 mM PMSF, 5 mM NaF, 0.08% NP-40, 0.5 mg of bovine serum albumin/ml, and 10% glycerol). Eluates were then layered on top of a 4.5-ml linear 10-to-40% glycerol gradient in GST-binding buffer and centrifuged for 16 h at 4°C at 40,000 rpm in an SW40 rotor (Beckman). Each fraction (600 µl) was then applied to a Western blot using anti-CBP or anti-RHA antibodies. Protein standards used were vitamin B12 (1.3 kDa), myoglobin (17 kDa), ovalbumin (44 kDa), ß-globulin (158 kDa), and thyroglobulin (667 kDa) (42, 54).

HAT assay. HAT activity in the glycerol density gradient fractions was assayed essentially as described previously (6). Briefly, the separated fractions were incubated with or without 10 µg of calf thymus histones (type IIA; Sigma) and 3H-labeled acetyl coenzyme A (acetyl-CoA) (4.7 Ci/mmol; Amersham) for 30 min at 30°C, spotted onto Whatman P-81 filters, and washed extensively with sodium carbonate buffer (pH 9.1). Radioactivity remaining on the filter was then quantitated by liquid scintillation counting.

Protein identification by MALDI-TOF MS. Protein bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels were excised and in-gel digested with trypsin according to published procedures (24, 43, 45). Eluted peptides were then prepared on the sampling plate for MALDI-TOF MS (Voyager DE-STR; Perseptive Biosystems). After analysis of each protein fragment mass, results were compared by using the MS-Fit program (University of California--San Francisco Mass Spectrometry Facility).

GST pulldown assay. A series of MR and RHA deletion mutants fused to GST were expressed in a baculovirus and in Escherichia coli, respectively, as described elsewhere (4). The predicted sizes of the expressed proteins were verified by SDS-PAGE. For GST pulldown assays, baculovirus- and bacterially expressed GST fusion proteins or GST bound to glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) was incubated at 30°C with [35S]methionine-labeled proteins expressed by in vitro translation using the TNT coupled transcription-translation system (Promega). Baculovirus-expressed GST-MR-DEF was preincubated with aldosterone (10-6 M) for 15 min at room temperature. After 2 h of incubation, free proteins were removed by washing the beads with NET-N+ buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl [pH 7.5], 0.5% NP-40, 1 mM PMSF, 1 mM DTT). Specifically bound proteins were eluted by boiling in SDS sample buffer and then analyzed by SDS-PAGE. After electrophoresis, radiolabeled proteins were visualized with an image analyzer (BAS1500; Fuji Film, Tokyo, Japan) (56).

Immunoprecipitation. After 293T cells were washed twice with ice-cold phosphate-buffered saline, the collected cells were resuspended in 1 ml of ice-cold lysis buffer (10 mM Tris-HCl [pH 4.7], 10 mM NaCl, 3 mM MgCl2, 0.5% [vol/vol] NP-40) and incubated on ice for 30 min; then they were centrifuged again for 5 min at 500 x g. The sedimented nuclear fractions were resuspended in TNE buffer (10 mM Tris-HCl [pH 7.5], 1% NP-40, 0.15 M NaCl, 1 mM EDTA) and incubated for 30 min on ice. After centrifugation, supernatants were used as whole-cell extracts of 293T cells for immunoprecipitation using an anti-FLAG M2 affinity resin (no. A2220; Sigma) after Western blotting with anti-FLAG M2 monoclonal, anti-HA, or anti-CBP antibodies.

Chromatin immunoprecipitation (ChIP) assay. HEK293 cells were cultured for 3 to 4 days in media supplemented with 10% charcoal-dextran stripped serum and were then infected with rat MR and RHA adenovirus expression constructs made by using the Adeno-X Expression System (Clontech Laboratories Inc.). After 2 days, cultures were treated with aldosterone (10-8 M) or hydrocortisone (10-8 M) for 45 min and immunoprecipitated with specific antibodies for MR, RHA, or CBP. Soluble chromatin was prepared by using an acetyl-histone H4 immunoprecipitation assay kit (Upstate Biotechnology) and was immunoprecipitated with antibodies against the indicated proteins. Extracted DNA samples were amplified with primer pairs Na-K-ATPase {alpha}1 (5'-CAGATTCTCAT TTTGGAATCTCGAAG-3' and 5'-GATCTCCTCTGGGACTCA-3') and {alpha}ENaC (5'-TTCCTTTCCAGCGCTGGCCAC-3' and 5'-CCTCCAACCTTGT CCAGACCC-3'). Optimized PCR conditions used to allow semiquantitative measurement were 20 cycles of 30 s at 96°C, 15 s at 56°C, and 1 min at 72°C. PCR products were visualized on 2% agarose-Tris-acetate EDTA gels.

Luciferase assay. 293T cells were transfected by using Lipofectin reagent (GIBCO BRL). A luciferase reporter plasmid containing two MREs and the thymidine kinase promoter (MREx2-tk-Luc) was cotransfected with expression vectors as indicated in the figure legends. Six hours after transfection, the medium was replaced with fresh medium containing 0.2% fetal bovine serum. At this time, aldosterone (10-9 M) or hydrocortisone (10-9 M) ligands were added, and cells were incubated for an additional 12 h. Preparation of cell extracts and dual luciferase assays were performed according to the manufacturer's protocols (Promega). Individual transfections, each consisting of triplicate wells, were repeated at least three times.


arrow
RESULTS
 
A HAT complex containing RHA and CBP interacts with rat MR AF-1a. To identify coactivator complexes for rat MR AF-1a, HeLa cell nuclear extract fractions, prepurified on phosphocellulose columns, were incubated with either GST-fused AF-1a protein or GST protein alone. After extensive washing, bound proteins were eluted by reduced glutathione and subjected to SDS-PAGE analysis. Protein bands which specifically bound to GST-MR-AF-1a protein were subjected to peptide mass fingerprinting by MALDI-TOF MS. Obtained masses and apparent molecular weights of the different polypeptides revealed that the fraction eluted from the AF-1a fusion protein contained RHA and CBP. Mass fingerprinting results were confirmed by Western blotting using specific antibodies against RHA and CBP (Fig. 1C). The presence of CBP in the purified fraction was consistent with our previous findings that CBP/p300 enhanced AF-1a activity (16) and with another study in which interaction between CBP and RHA was observed (36). Thus, the AF-1a region may interact with a coactivator complex containing both CBP and RHA.



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 1. Purification and identification of MR AF-1a-binding complexes. (A) Schematic representation of rat MR activation domains and deletion mutants. AF-1a and AF-1b are ligand-independent activation regions within the rat MR A/B domain. GST-fused MR AF-1a (GST-MR-AF-1a) was used as bait for binding-complex purification. A DNA binding domain (DBD) was present in all rat MR deletion mutants (FLAG-AF1a, FLAG-AF1b, FLAG-AF2, and FLAG-MR{Delta}AF1a). (B) Purification scheme for MR AF-1a interactants. Nuclear extracts from HeLa S3 cells were applied to P11 phosphocellulose columns. After extensive washes with wash buffer (20 mM Tris-HCl [pH 7.9], 0.2 mM EDTA, 0.05% NP-40, 10% glycerol, 0.5 mM PMSF, 1 mM DTT) containing 0.15 M KCl, bound proteins were eluted with wash buffer containing 1.0 M KCl. Eluted fractions were then incubated with immobilized GST-MR-AF-1a, and MR AF1a-interacting proteins were eluted by using N-lauryl sarcosine. (C) Identification of MR AF-1a interactants. The indicated fractions were subjected to SDS-PAGE followed by silver staining. Total HeLa S3 nuclear extracts (NE) (lane 1), a fraction eluted from a P11 column (P11) (lane 2), and eluted fractions from GST and GST-MR-AF-1a (lanes 3 and 4) are shown. Proteins eluted from GST-MR-AF-1a (lane 4) were identified by MS analysis. Lower panels show Western blotting for each fraction using antibodies against RHA or CBP.

AF-1a region-interacting proteins were further fractionated according to molecular mass by using a glycerol density gradient. Since CBP has HAT activity, HAT activity for each fraction was assessed (Fig. 2B). Proteins in each fraction were separated by SDS-PAGE in parallel and were either silver stained or analyzed by Western blotting using specific antibodies against RHA and CBP (Fig. 2A and C, respectively). RHA and CBP were detected in fractions that possessed high HAT activity and were included in a multiprotein complex of more than 670 kDa, which suggested that a CBP-containing HAT multiprotein complex (designated the RHA/CBP complex) bound MR AF-1a (Fig. 2C).



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 2. A HAT complex containing RHA and CBP interacts with MR AF-1a. (A) Glycerol density gradient analysis. Fractions eluted on a P11 column were passed over an immobilized GST-MR-AF-1a column. Protein complexes bound to GST-MR-AF-1a were then dissociated by reduced glutathione and applied to 10-to-40% glycerol density gradients. Each fraction was subjected to SDS-PAGE followed by silver staining. The positions of marker proteins with known molecular masses on the gradient are indicated. (B) HAT activity in the glycerol density gradient fractions. The indicated fractions were incubated with or without free histones, together with 3H-labeled acetyl-CoA, and assayed for HAT activity in a filter-binding assay as described in Materials and Methods. HAT activity is quantitated as counts per minute of 3H-labeled acetate transferred from acetyl-CoA to histones. (C) Western blot analysis of glycerol density gradient fractions. To identify the proteins contained in each gradient fraction, Western blot analysis was performed with specific antibodies against RHA or CBP.

RHA interacts directly with MR AF-1a. To test whether RHA and CBP interacted directly with the AF-1a region, a GST pulldown assay was performed by using a series of GST-fused MR and RHA deletion mutants, together with in vitro-translated proteins. While RHA directly bound the N-terminal region (amino acids 1 to 169) of MR, CBP did not bind to any of the MR A/B domain deletion mutants (Fig. 3A). We then tested for interaction between RHA and AF-1a or CBP. The AF-1a region exhibited affinity for the N-terminal region (amino acids 1 to 262) of RHA (Fig. 3B). As expected from previous studies, we observed direct binding of CBP to the basic region of RHA (36). However, we failed with the N-terminal deletion mutants to map the core regions for the interactions, because RHA and CBP could not be distinguished in the interactions. The physical interactions appeared to require that the protein structures of the interacting regions be intact. These results suggested that RHA within the RHA/CBP complex acted as the interface for the AF-1a region.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 3. RHA interacts directly with MR AF-1a. (A) RHA, but not CBP, interacts directly with MR AF-1a. A GST pulldown assay was performed as described in Materials and Methods. A series of MR deletion mutants fused to GST were expressed by a baculovirus, and the GST fusion proteins were immobilized on glutathione-Sepharose beads. In vitro-translated RHA and CBP were incubated with glutathione-Sepharose beads loaded with each MR mutant fused to GST (for GST-MR-DEF, in the absence and presence of 10-6 M aldosterone). Bound proteins were subjected to SDS-PAGE followed by autoradiography. rMR, rat MR; aldo, aldosterone. (B) Mapping of the MR binding region to the N-terminal domain of RHA. A series of RHA deletion mutants fused to GST were expressed by E. coli and immobilized on glutathione-Sepharose beads. In vitro-translated MR AF-1a and CBP were then incubated with the glutathione-Sepharose beads loaded with each RHA mutant fusion protein. Bound proteins were subjected to SDS-PAGE followed by autoradiography.

RHA/CBP complexes are recruited to MR bound on the target gene promoters in the presence of aldosterone but not hydrocortisone. We then used coimmunoprecipitation to test whether interaction between AF-1a and RHA/CBP complexes took place in living cells. By use of antibodies against FLAG and HA, both HA-RHA fusion protein and endogenous CBP were detected by Western blotting in AF-1a immunoprecipitates from extracts of expression vector-transfected 293T cells. Increased amounts of CBP were immunoprecipitated with AF-1a in cells that overexpressed RHA (Fig. 4A, lane 4), which supported our finding that RHA mediated the indirect association of CBP with MR AF-1a. We next tested for in vivo interaction between full-length MR and RHA/CBP complexes. Like the AF-1a region, full-length MR also coimmunoprecipitated with CBP and RHA in an aldosterone-dependent manner, with increased CBP retention in immunoprecipitates from RHA-overexpressing cells (Fig. 4B, lanes 1 to 4). However, in the presence of hydrocortisone, coimmunoprecipitation of MR and RHA was not detected and no increase in the level of MR-associated CBP was observed when RHA was overexpressed (Fig. 4B, lanes 5 to 8).



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 4. Ligand-selective recruitment of RHA-CBP complexes to MR AF-1a in vivo. (A) RHA/CBP complexes interact with MR AF-1a in vivo. 293T cells were cotransfected with or without 5 µg of pc-DNA-FLAG-MR-AF-1a, pc-DNA-HA-RHA, or pc-DNA-CBP. Cells were lysed in TNE buffer and subjected to immunoprecipitation (IP) using an anti-FLAG ({alpha}FLAG) affinity resin. Precipitates were Western blotted by using antibodies against FLAG, HA, or CBP as indicated. (B) Aldosterone, but not hydrocortisone, induces interaction between RHA/CBP complexes and MR. 293T cells were cotransfected with or without 5 µg of pc-DNA-FLAG-MR, pc-DNA-HA-RHA, or pc-DNA-CBP in the presence or absence of 10-8 M aldosterone or hydrocortisone. Cells were lysed in TNE buffer and subjected to immunoprecipitation using an anti-FLAG affinity resin. Precipitates were Western blotted with antibodies against FLAG, HA, or CBP as indicated. (C) RHA/CBP complexes are recruited to the MR target gene promoters Na-K-ATPase {alpha}1 and {alpha}ENaC in an aldosterone-dependent manner. HEK293 cells were transfected with an adenovirus expressing rat MR and RHA. Soluble chromatin was prepared from HEK293 cells treated with 10-8 M aldosterone (aldo) or hydrocortisone (HC) for 45 min and was immunoprecipitated with antibodies against MR, RHA, or CBP. (i.e., the ChIP assay was performed). DNA was then extracted and amplified with pairs of primers covering the Na-K-ATPase {alpha}1 and {alpha}ENaC gene promoter regions as indicated.

To further investigate whether the RHA/CBP complex was indeed recruited to MR in the presence of aldosterone rather than hydrocortisone in living cells, we performed a ChIP assay using promoters from the MR target genes encoding the Na-K-ATPase {alpha}1 subunit and the {alpha} subunit of the epithelial sodium channel ({alpha}ENaC) (29, 35, 46). MR was recruited together with RHA/CBP complexes to the promoter regions of both target genes in the presence of aldosterone, but not in the presence of hydrocortisone, supporting the hypothesis that aldosterone selectively induced the recruitment of RHA/CBP complexes to MR (Fig. 4C).

RHA and CBP cooperatively enhance MR AF-1a transactivation. To test whether the aldosterone-induced recruitment of RHA/CBP complexes potentiated MR function, a transient expression assay using a luciferase reporter with MREs in the promoter was performed. Full-length and deletion mutant MR expression plasmids were cotransfected into 293T cells in the presence or absence of aldosterone. The results of this assay showed that the expression of RHA or CBP enhanced both AF-1a region transactivation and the aldosterone-induced transactivation function of full-length MR. RHA and CBP exhibited cooperative activity in transactivational enhancement of both AF-1a and full-length MR, which was consistent with the hypothesis that RHA and CBP act as part of the same coactivator complex. The lack of synergism between RHA and CBP in the AF-1a potentiation may be due to the relative abundances of the two factors. The transactivation functions of the AF-1b and AF-2 regions, which did not bind RHA, were not potentiated by RHA, while CBP and TIF2 potently coactivated AF-2 (Fig. 5).



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 5. RHA and CBP cooperatively potentiate AF-1a and aldosterone-bound MR. 293T cells were cotransfected with 0.25 µg of a luciferase reporter plasmid bearing progesterone response elements (PREx2-tk-luc), 50 ng of an expression vector containing an MR deletion mutant tagged with FLAG, and 0.3 µg of either pc-DNA, pc-DNA-HA-RHA, pc-DNA-CBP, or pc-DNA-TIF2 in the presence (+) or absence (-) of aldosterone (10-9 M). Bars show the fold change in luciferase activity relative to the activity of the MR deletion mutant (in the presence of 10-9 M aldosterone) or the activity of pc-DNA-FLAG-MR-FL (in the presence of 10-9 M aldosterone) without transfection of coactivators.

Interaction with RNA polymerase II is not essential for MR transactivation by RHA. It has been reported previously that RHA directly interacts with RNA polymerase II through the minimal transactivation domain (MTAD) within the RHA molecule (4). However, RNA polymerase II was not detected in the glycerol density gradient fractions that contained the RHA/CBP complexes (data not shown). Therefore, using RHA mutants RHA{Delta}MTAD and RHA W339A, which do not bind RNA polymerase II, we examined whether interaction between RHA and RNA polymerase II was required for the enhancement of AF-1a function by RHA/CBP complexes (4). Since both mutants were still functional, our results suggested that association between RNA polymerase II and RHA was not essential for RHA/CBP complex-mediated potentiation of AF-1a transactivation (Fig. 6).



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 6. RHA-RNA polymerase II binding is not necessary for potentiation of MR AF-1 by RHA/CBP complexes. (A) Schematic representation of the RHA mutants. MTAD acts as the RNA polymerase II interacting domain. However, the point mutant RHA W339A prevents this interaction. (B) RHA-RNA polymerase II binding is not necessary for potentiation of MR AF-1 by the RHA/CBP complex. 293T cells were cotransfected with 0.25 µg of a luciferase reporter plasmid bearing progesterone response elements (PREx2-tk-luc), 50 ng of an expression vector containing pc-DNA-FLAG-MR-AF-1a or pc-DNA-FLAG-MR, and 0.3 µg of either pc-DNA-HA-RHA, pc-DNA-HA-RHA{Delta}MTAD, pc-DNA-HA-RHAW339A, or pc-DNA-CBP in the presence (+) or absence (-) of aldosterone (10-9 M). Bars show the fold change in luciferase activity relative to the activity of FLAG-MR-AF1a (AF-1a) or FLAG-MR (MR) in the presence of aldosterone (10-9 M) without transfection of coactivators. NR, nuclear receptor.

RHA potentiates MR in a ligand-selective manner. Our results suggested that recruitment of RHA/CBP complexes to MR bound to target gene promoters was ligand selective. Therefore, we next investigated whether RHA/CBP complexes potentiated MR in a ligand-selective manner. In agreement with previous results, RHA was active only for aldosterone-bound MR (Fig. 7A). An MR mutant that lacked the AF-1a region (MR{Delta}AF1a) lost potentiation of aldosterone-induced transactivation by RHA (Fig. 7B). Thus, aldosterone binding to MR may induce an altered conformation of the A/B domain, which would then result in increased access of RHA/CBP complexes to the A/B domain. In contrast, the AF-1a region of hydrocortisone-bound MR may be in a conformation that blocks RHA/CBP complex association.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 7. RHA and CBP cooperatively potentiate MR in a ligand-selective manner. (A) Aldosterone-dependent potentiation of the MR transactivation function by the RHA/CBP protein complex was observed, but hydrocortisone-dependent potentiation was not. (B) AF-1a is essential for the ligand-selective potentiation by the RHA/CBP complex. 293T cells were cotransfected with 0.25 µg of a luciferase reporter plasmid bearing progesterone response elements (PREx2-tk-luc), 50 ng of an MR deletion mutant expression vector, and 0.3 µg of either pc-DNA-HA-RHA, pc-DNA-CBP, or pc-DNA-TIF2 in the presence (+) or absence (-) of either aldosterone (10-9 M) or hydrocortisone (10-9 M). Bars show the fold change in luciferase activity relative to the activity of FLAG-MR-FL (MR) or FLAG-MR{Delta}AF1a (MR{Delta}AF1a) in the presence of aldosterone (10-9 M) without transfection of coactivators.


arrow
DISCUSSION
 
The A/B domain is poorly conserved among the members of the nuclear receptor superfamily, and the function of the A/B domain in terms of ligand-induced transactivation and coactivator action is not fully understood. In a previous study, we reported that the rat MR A/B domain harbored two AF-1 regions, designated AF-1a and AF-1b. While AF-1b and AF-2 activities were enhanced by TIF2 and CBP/p300, AF-1a activity was potentiated by CBP/p300 but not by TIF2 (16). Therefore, it was thought likely that AF-1a was potentiated by different coactivator complexes that contained CBP/p300 rather than TIF2. In the present paper, we have shown that the RHA/CBP complex acts as a coactivator of AF-1a activity. Glycerol density gradient analysis showed that RHA and CBP were present in fractions that possessed high HAT activity and were likely to contain multiprotein complexes of more than 670 kDa. Together with our previous observation that TIF2 was unable to potentiate AF-1a function, our present study suggests that RHA/CBP complexes probably contribute, at least in part, to the observed HAT activity of AF-1a-bound protein fractions (37).

RHA has been reported to be a component of the holoenzyme complex with RNA polymerase II, as well as to interact with CBP (36). In agreement with this previous study, RHA cosedimented with CBP in the same glycerol density gradient fractions, and RHA potentiated the interaction between CBP and the AF-1a region, leading to enhanced CBP-stimulated AF-1a activity. However, in contrast to the findings of previous studies (4, 12, 36), RNA polymerase II was not detected in the glycerol density gradient fractions that contained RHA and CBP (data not shown). Furthermore, the potentiation of AF-1a function by RHA mutants that lacked the putative interacting region for RNA polymerase II was comparable to that by wild-type RHA, which indicated that the RHA coactivator function for MR AF-1a required CBP but did not require direct association with RNA polymerase II.

SDS-PAGE analysis revealed that several proteins cosedimented with RHA and CBP. Unfortunately, the mass fingerprinting method we employed was unable to identify these other proteins. The failure to ascertain the identity of these other RHA/CBP complex components may be due to their relatively low abundance. Given the fact that MR AF-1a-associated complexes exhibited a broad spectrum of molecular weights within the glycerol density gradient fractions, it is likely that AF-1a-interacting complexes other than the RHA/CBP complex exist in the nucleus. Given the observed sizes of the HAT complexes on the glycerol density gradient, only some of the AF-1a-associated proteins appear to form the RHA/CBP complex.

Comparison of the crystal structures of ligand-binding domains from several nuclear receptors revealed that cognate ligand binding induced the repositioning of the C-terminal {alpha}-helical structure (H12) to form a hydrophobic groove, which then served as an interaction surface for AF-2 coactivators (7, 9, 18). We have previously shown that for the vitamin D receptor, some synthetic ligands can induce different H12 configurations that create recognition surfaces for the ligand-selective recruitment of various coactivators (47). However, GST pulldown and luciferase assays using MR and known AF-2 coactivators failed to detect ligand-selective coactivator recruitment in MR (data not shown). In this study we showed that full-length MR recruited RHA/CBP complexes through the AF-1a region and that this enhanced transactivation function was ligand dependent. Considering these results together with the results of previous studies showing the different contributions of AF-1 activity to full-length MR activity induced by endogenous aldosterone and hydrocortisone (22, 26), the two different ligands appear to induce different A/B region conformations. Thus, it appears that different nuclear receptor ligands may induce different conformations not only in E/F domains but also in A/B domains (44, 51), so that ligand-selective coactivator recruitment could be a feature of both E/F and A/B domains (28).

It is thought that the specific actions of the two MR ligands observed in vivo are at least partially mediated by the restricted tissue expression of the enzyme 11ßHSD2 and the subsequent inactivation of hydrocortisone in MR target tissues. While the balance between MR and glucocorticoid receptor expression levels in a given tissue or cell may lead to ligand-specific actions, these factors appear to be insufficient to fully confer ligand specificity, particularly in nonepithelial mineralocorticoid target tissues (e.g., the heart and central nervous system), where 11ßHSD2 is not expressed (33). We show here that the recruitment of RHA/CBP coactivator complexes may discriminate between the actions of the two endogenous MR ligands. The tissue-specific activity of the MR ligands suggests the possible existence of tissue-specific components of coactivator complexes (57, 59, 60). A recent report using MR knockout mice shows that MR is essential for the neurogenesis of granule cells in the hippocampus (17). As the ratio between serum aldosterone and hydrocortisone levels varies during neuronal development, it is thought that MR functions at a critical stage during neuronal development. Therefore, to better understand MR ligand-specific activity at the molecular level, it will be of great interest to assess the expression and physiological function of the RHA/CBP complex in different tissues.


arrow
ACKNOWLEDGMENTS
 
We thank T. Kase of Kureha Chemical Industry Co. Ltd. for skillful preparation of baculovirus and insect cell cultures. We also thank E. Murayama of the Department of Applied Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, for help with protein identification.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Institute of Molecular and Cellular Bioscience, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan. Phone: 81-3-5841-7891. Fax: 81-3-5841-8477. E-mail: uskato{at}mail.ecc.u-tokyo.ac.jp. Back


arrow
REFERENCES
 
    1
  1. Agarwal, M. K. 1994. Perspectives in receptor-mediated mineralocorticoid hormone action. Pharmacol. Rev. 46:67-87.[Medline]
    2. 2
  2. Anderson, S. F., B. P. Schlegel, T. Nakajima, E. S. Wolpin, and J. D. Parvin. 1998. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19:254-256.[CrossRef][Medline]
    3. 3
  3. Anzick, S. L., J. Kononen, R. L. Walker, D. O. Azorsa, M. M. Tanner, X. Y. Guan, G. Sauter, O. P. Kallioniemi, J. M. Trent, and P. S. Meltzer. 1997. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968.[Abstract/Free Full Text]
    4. 4
  4. Aratani, S., R. Fujii, T. Oishi, H. Fujita, T. Amano, T. Ohshima, M. Hagiwara, A. Fukamizu, and T. Nakajima. 2001. Dual roles of RNA helicase A in CREB-dependent transcription. Mol. Cell. Biol. 21:4460-4469.[Abstract/Free Full Text]
    5. 5
  5. Berger, S., M. Bleich, W. Schmid, T. J. Cole, J. Peters, H. Watanabe, W. Kriz, R. Warth, R. Greger, and G. Schutz. 1998. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc. Natl. Acad. Sci. USA 95:9424-9429.[Abstract/Free Full Text]
    6. 6
  6. Brownell, J. E., and C. D. Allis. 1995. An activity gel assay detects a single, catalytically active histone acetyltransferase subunit in Tetrahymena macronuclei. Proc. Natl. Acad. Sci. USA 92:6364-6368.[Abstract/Free Full Text]
    7. 7
  7. Brzozowski, A. M., A. C. Pike, Z. Dauter, R. E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. L. Greene, J. A. Gustafsson, and M. Carlquist. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758.[CrossRef][Medline]
    8. 8
  8. Endoh, H., K. Maruyama, Y. Masuhiro, Y. Kobayashi, M. Goto, H. Tai, J. Yanagisawa, D. Metzger, S. Hashimoto, and S. Kato. 1999. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol. Cell. Biol. 19:5363-5372.[Abstract/Free Full Text]
    9. 9
  9. Fagart, J., J. M. Wurtz, A. Souque, C. Hellal-Levy, D. Moras, and M. E. Rafestin-Oblin. 1998. Antagonism in the human mineralocorticoid receptor. EMBO J. 17:3317-3325.[CrossRef][Medline]
    10. 10
  10. Farman, N. 1999. Molecular and cellular determinants of mineralocorticoid selectivity. Curr. Opin. Nephrol. Hypertens. 8:45-51.[CrossRef][Medline]
    11. 11
  11. Freedman, L. P. 1999. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97:5-8.[CrossRef][Medline]
    12. 12
  12. Fujii, R., M. Okamoto, S. Aratani, T. Oishi, T. Ohshima, K. Taira, M. Baba, A. Fukamizu, and T. Nakajima. 2001. A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1. J. Biol. Chem. 276:5445-5451.[Abstract/Free Full Text]
    13. 13
  13. Funder, J., and K. Myles. 1996. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137:5264-5268.[Abstract]
    14. 14
  14. Funder, J. W. 1998. Aldosterone action: fact, failure and the future. Clin. Exp. Pharmacol. Physiol. Suppl. 25:S47-S50.[Medline]
    15. 15
  15. Funder, J. W., P. T. Pearce, R. Smith, and A. I. Smith. 1988. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585.[Abstract/Free Full Text]
    16. 16
  16. Fuse, H., H. Kitagawa, and S. Kato. 2000. Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol. Endocrinol. 14:889-899.[Abstract/Free Full Text]
    17. 17
  17. Gass, P., O. Kretz, D. P. Wolfer, S. Berger, F. Tronche, H. M. Reichardt, C. Kellendonk, H. P. Lipp, W. Schmid, and G. Schutz. 2000. Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep. 1:447-451.[CrossRef][Medline]
    18. 18
  18. Gill, R. K., L. M. Atkins, B. W. Hollis, and N. H. Bell. 1998. Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. Mol. Endocrinol. 12:57-65.[Abstract/Free Full Text]
    19. 19
  19. Glass, C. K., and M. G. Rosenfeld. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121-141.[Free Full Text]
    20. 20
  20. Gomez-Sanchez, E. P., C. M. Fort, and C. E. Gomez-Sanchez. 1990. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am. J. Physiol. 258:E482-E484.[Abstract/Free Full Text]
    21. 21
  21. Gomez-Sanchez, E. P., M. T. Venkataraman, D. Thwaites, and C. Fort. 1990. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 258:E649-E653.[Abstract/Free Full Text]
    22. 22
  22. Govindan, M. V., and N. Warriar. 1998. Reconstitution of the N-terminal transcription activation function of human mineralocorticoid receptor in a defective human glucocorticoid receptor. J. Biol. Chem. 273:24439-24447.[Abstract/Free Full Text]
    23. 23
  23. Gu, W., S. Malik, M. Ito, C. X. Yuan, J. D. Fondell, X. Zhang, E. Martinez, J. Qin, and R. G. Roeder. 1999. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol. Cell 3:97-108.[CrossRef][Medline]
    24. 24
  24. Hellman, U., C. Wernstedt, J. Gonez, and C. H. Heldin. 1995. Improvement of an "in-gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. Anal. Biochem. 224:451-455.[CrossRef][Medline]
    25. 25
  25. Hittelman, A. B., D. Burakov, J. A. Iniguez-Lluhi, L. P. Freedman, and M. J. Garabedian. 1999. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J. 18:5380-5388.[CrossRef][Medline]
    26. 26
  26. Jausons-Loffreda, N., C. Chabret, and M. Pons. 1994. Role of the A/B region of the human mineralocorticoid receptor in aldosterone response selectivity. Biochem. Biophys. Res. Commun. 205:1610-1616.[CrossRef][Medline]
    27. 27
  27. Kobayashi, T., and S. Kato. 2000. Hallucination of soliloquy: speaking component and hearing component of schizophrenic hallucinations. Psychiatry Clin. Neurosci. 54:531-536.[Medline]
    28. 28
  28. Kodera, Y., K. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato. 2000. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem. 275:33201-33204.[Abstract/Free Full Text]
    29. 29
  29. Kolla, V., N. M. Robertson, and G. Litwack. 1999. Identification of a mineralocorticoid/glucocorticoid response element in the human Na/K ATPase {alpha}1 gene promoter. Biochem. Biophys. Res. Commun. 266:5-14.[CrossRef][Medline]
    30. 30
  30. Lanz, R. B., N. J. McKenna, S. A. Onate, U. Albrecht, J. Wong, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1999. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97:17-27.[CrossRef][Medline]
    31. 31
  31. Lees, J. A., S. E. Fawell, and M. G. Parker. 1989. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res. 17:5477-5488.[Abstract/Free Full Text]
    32. 32
  32. Le Menuet, D., R. Isnard, M. Bichara, S. Viengchareun, M. Muffat-Joly, F. Walker, M. C. Zennaro, and M. Lombes. 2001. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J. Biol. Chem. 276:38911-38920.[Abstract/Free Full Text]
    33. 33
  33. Lim-Tio, S. S., and P. J. Fuller. 1998. Intracellular signaling pathways confer specificity of transactivation by mineralocorticoid and glucocorticoid receptors. Endocrinology 139:1653-1661.[Abstract/Free Full Text]
    34. 34
  34. Lombes, M., S. Kenouch, A. Souque, N. Farman, and M. E. Rafestin-Oblin. 1994. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11ß-hydroxysteroid dehydrogenase. Endocrinology 135:834-840.[Abstract]
    35. 35
  35. Mick, V. E., O. A. Itani, R. W. Loftus, R. F. Husted, T. J. Schmidt, and C. P. Thomas. 2001. The alpha-subunit of the epithelial sodium channel is an aldosterone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis-elements in the 5'-flanking region of the gene. Mol. Endocrinol. 15:575-588.[Abstract/Free Full Text]
    36. 36
  36. Nakajima, T., C. Uchida, S. F. Anderson, C. G. Lee, J. Hurwitz, J. D. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112.[CrossRef][Medline]
    37. 37
  37. Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959.[CrossRef][Medline]
    38. 38
  38. Onate, S. A., S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357.[Abstract/Free Full Text]
    39. 39
  39. Pellizzoni, L., B. Charroux, J. Rappsilber, M. Mann, and G. Dreyfuss. 2001. A functional interaction between the survival motor neuron complex and RNA polymerase II. J. Cell Biol. 152:75-85.[Abstract/Free Full Text]
    40. 40
  40. Pitt, B., F. Zannad, W. J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341:709-717.[Abstract/Free Full Text]
    41. 41
  41. Rachez, C., B. D. Lemon, Z. Suldan, V. Bromleigh, M. Gamble, A. M. Naar, H. Erdjument-Bromage, P. Tempst, and L. P. Freedman. 1999. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824-828.[CrossRef][Medline]
    42. 42
  42. Rachez, C., Z. Suldan, J. Ward, C. P. Chang, D. Burakov, H. Erdjument-Bromage, P. Tempst, and L. P. Freedman. 1998. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev. 12:1787-1800.[Abstract/Free Full Text]
    43. 43
  43. Rosenfeld, J., J. Capdevielle, J. C. Guillemot, and P. Ferrara. 1992. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal. Biochem. 203:173-179.[CrossRef][Medline]
    44. 44
  44. Shao, D., S. M. Rangwala, S. T. Bailey, S. L. Krakow, M. J. Reginato, and M. A. Lazar. 1998. Interdomain communication regulating ligand binding by PPAR-{gamma}. Nature 396:377-380.[CrossRef][Medline]
    45. 45
  45. Shevchenko, A., M. Wilm, O. Vorm, and M. Mann. 1996. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem. 68:850-858.[Medline]
    46. 46
  46. Shull, M. M., D. G. Pugh, and J. B. Lingrel. 1990. The human Na, K-ATPase {alpha}1 gene: characterization of the 5'-flanking region and identification of a restriction fragment length polymorphism. Genomics 6:451-460.[CrossRef][Medline]
    47. 47
  47. Takeyama, K., Y. Masuhiro, H. Fuse, H. Endoh, A. Murayama, S. Kitanaka, M. Suzawa, J. Yanagisawa, and S. Kato. 1999. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol. Cell. Biol. 19:1049-1055.[Abstract/Free Full Text]
    48. 48
  48. Tanner, N. K., and P. Linder. 2001. DExD/H box RNA helicases: from generic motors to specific dissociation functions. Mol. Cell 8:251-262.[CrossRef][Medline]
    49. 49
  49. Tora, L., J. White, C. Brou, D. Tasset, N. Webster, E. Scheer, and P. Chambon. 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487.[CrossRef][Medline]
    50. 50
  50. Torchia, J., D. W. Rose, J. Inostroza, Y. Kamei, S. Westin, C. K. Glass, and M. G. Rosenfeld. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684.[CrossRef][Medline]
    51. 51
  51. Trapp, T., and F. Holsboer. 1995. Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem. Biophys. Res. Commun. 215:286-291.[CrossRef][Medline]
    52. 52
  52. Tsai, S. Y., M. J. Tsai, and B. W. O'Malley. 1989. Cooperative binding of steroid hormone receptors contributes to transcriptional synergism at target enhancer elements. Cell 57:443-448.[CrossRef][Medline]
    53. 53
  53. Voegel, J. J., M. J. Heine, C. Zechel, P. Chambon, and H. Gronemeyer. 1996. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:3667-3675.[Medline]
    54. 54
  54. Watanabe, M., J. Yanagisawa, H. Kitagawa, K. Takeyama, S. Ogawa, Y. Arao, M. Suzawa, Y. Kobayashi, T. Yano, H. Yoshikawa, Y. Masuhiro, and S. Kato. 2001. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J. 20:1341-1352.[CrossRef][Medline]
    55. 55
  55. Wu, X., H. Li, and J. D. Chen. 2001. The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-1-specific coactivator of estrogen receptor. J. Biol. Chem. 276:23962-23968.[Abstract/Free Full Text]
    56. 56
  56. Yanagisawa, J., Y. Yanagi, Y. Masuhiro, M. Suzawa, M. Watanabe, K. Kashiwagi, T. Toriyabe, M. Kawabata, K. Miyazono, and S. Kato. 1999. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317-1321.[Abstract/Free Full Text]
    57. 57
  57. Young, M. 1995. Adrenal steroids and cardiac fibrosis. Steroids 60:133-136.[CrossRef][Medline]
    58. 58
  58. Young, M., G. Head, and J. Funder. 1995. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 269:E657-E662.
    59. 59
  59. Young, M. J., and J. W. Funder. 1996. Mineralocorticoids, salt, hypertension: effects on the heart. Steroids 61:233-235.[CrossRef][Medline]
    60. 60
  60. Zennaro, M. C., D. Le Menuet, S. Viengchareun, F. Walker, D. Ricquier, and M. Lombes. 1998. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J. Clin. Investig. 101:1254-1260.[Medline]
    61. 61
  61. Zennaro, M. C., A. Souque, S. Viengchareun, E. Poisson, M. Lombes, C. Rachez, and L. P. Freedman. 2001. A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action. Mol. Endocrinol. 15:1586-1598.[Abstract/Free Full Text]

Molecular and Cellular Biology, June 2002, p. 3698-3706, Vol. 22, No. 11
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.11.3698-3706.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pippal, J. B., Yao, Y., Rogerson, F. M., Fuller, P. J. (2009). Structural and Functional Characterization of the Interdomain Interaction in the Mineralocorticoid Receptor. Mol. Endocrinol. 23: 1360-1370 [Abstract] [Full Text]  
  • Yang, J., Young, M. J (2009). The mineralocorticoid receptor and its coregulators. J Mol Endocrinol 43: 53-64 [Abstract] [Full Text]  
  • Pippal, J. B, Fuller, P. J (2008). Structure-function relationships in the mineralocorticoid receptor. J Mol Endocrinol 41: 405-413 [Abstract] [Full Text]  
  • Weber, M., Wehling, M., Losel, R. (2008). Proteins interact with the cytosolic mineralocorticoid receptor depending on the ligand. Am. J. Physiol. Heart Circ. Physiol. 295: H361-H365 [Abstract] [Full Text]  
  • Akimoto, C., Kitagawa, H., Matsumoto, T., Kato, S. (2008). Spermatogenesis-specific association of SMCY and MSH5.. GENES CELLS 13: 623-633 [Abstract] [Full Text]  
  • Molnar, G. A., Lindschau, C., Dubrovska, G., Mertens, P. R., Kirsch, T., Quinkler, M., Gollasch, M., Wresche, S., Luft, F. C., Muller, D. N., Fiebeler, A. (2008). Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells. Hypertension 51: 1372-1378 [Abstract] [Full Text]  
  • Kitagawa, H., Yamaoka, I., Akimoto, C., Kase, I., Mezaki, Y., Shimizu, T., Kato, S. (2007). A reduction state potentiates the glucocorticoid response through receptor protein stabilization.. GENES CELLS 12: 1281-1287 [Abstract] [Full Text]  
  • Caprio, M., Feve, B., Claes, A., Viengchareun, S., Lombes, M., Zennaro, M.-C. (2007). Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 21: 2185-2194 [Abstract] [Full Text]  
  • Takeda, A.-N., Pinon, G. M., Bens, M., Fagart, J., Rafestin-Oblin, M.-E., Vandewalle, A. (2007). The Synthetic Androgen Methyltrienolone (R1881) Acts as a Potent Antagonist of the Mineralocorticoid Receptor. Mol. Pharmacol. 71: 473-482 [Abstract] [Full Text]  
  • DeRijk, R. H., Wust, S., Meijer, O. C., Zennaro, M.-C., Federenko, I. S., Hellhammer, D. H., Giacchetti, G., Vreugdenhil, E., Zitman, F. G., de Kloet, E. R. (2006). A Common Polymorphism in the Mineralocorticoid Receptor Modulates Stress Responsiveness. J. Clin. Endocrinol. Metab. 91: 5083-5089 [Abstract] [Full Text]  
  • Mo, R., Rao, S. M., Zhu, Y.-J. (2006). Identification of the MLL2 Complex as a Coactivator for Estrogen Receptor {alpha}. J. Biol. Chem. 281: 15714-15720 [Abstract] [Full Text]  
  • Fuller, P. J., Young, M. J. (2005). Mechanisms of Mineralocorticoid Action. Hypertension 46: 1227-1235 [Abstract] [Full Text]  
  • Pascual-Le Tallec, L., Lombes, M. (2005). The Mineralocorticoid Receptor: A Journey Exploring Its Diversity and Specificity of Action. Mol. Endocrinol. 19: 2211-2221 [Abstract] [Full Text]  
  • Hultman, M. L., Krasnoperova, N. V., Li, S., Du, S., Xia, C., Dietz, J. D., Lala, D. S., Welsch, D. J., Hu, X. (2005). The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms. Mol. Endocrinol. 19: 1460-1473 [Abstract] [Full Text]  
  • Pascual-Le Tallec, L., Simone, F., Viengchareun, S., Meduri, G., Thirman, M. J., Lombes, M. (2005). The Elongation Factor ELL (Eleven-Nineteen Lysine-Rich Leukemia) Is a Selective Coregulator for Steroid Receptor Functions. Mol. Endocrinol. 19: 1158-1169 [Abstract] [Full Text]  
  • Walther, R. F., Atlas, E., Carrigan, A., Rouleau, Y., Edgecombe, A., Visentin, L., Lamprecht, C., Addicks, G. C., Hache, R. J. G., Lefebvre, Y. A. (2005). A Serine/Threonine-rich Motif Is One of Three Nuclear Localization Signals That Determine Unidirectional Transport of the Mineralocorticoid Receptor to the Nucleus. J. Biol. Chem. 280: 17549-17561 [Abstract] [Full Text]  
  • Mischo, H. E., Hemmerich, P., Grosse, F., Zhang, S. (2005). Actinomycin D Induces Histone {gamma}-H2AX Foci and Complex Formation of {gamma}-H2AX with Ku70 and Nuclear DNA Helicase II. J. Biol. Chem. 280: 9586-9594 [Abstract] [Full Text]  
  • Meijer, O. C., Kalkhoven, E., van der Laan, S., Steenbergen, P. J., Houtman, S. H., Dijkmans, T. F., Pearce, D., de Kloet, E. R. (2005). Steroid Receptor Coactivator-1 Splice Variants Differentially Affect Corticosteroid Receptor Signaling. Endocrinology 146: 1438-1448 [Abstract] [Full Text]  
  • Marissal-Arvy, N., Lombes, M., Petterson, J., Moisan, M.-P., Mormede, P. (2004). Gain of Function Mutation in the Mineralocorticoid Receptor of the Brown Norway Rat. J. Biol. Chem. 279: 39232-39239 [Abstract] [Full Text]  
  • Sartorato, P., Cluzeaud, F., Fagart, J., Viengchareun, S., Lombes, M., Zennaro, M.-C. (2004). New Naturally Occurring Missense Mutations of the Human Mineralocorticoid Receptor Disclose Important Residues Involved in Dynamic Interactions with Deoxyribonucleic Acid, Intracellular Trafficking, and Ligand Binding. Mol. Endocrinol. 18: 2151-2165 [Abstract] [Full Text]  
  • Obradovic, D., Tirard, M., Nemethy, Zs., Hirsch, O., Gronemeyer, H., Almeida, O. F. X. (2004). DAXX, FLASH, and FAF-1 Modulate Mineralocorticoid and Glucocorticoid Receptor-Mediated Transcription in Hippocampal Cells--Toward a Basis for the Opposite Actions Elicited by Two Nuclear Receptors?. Mol. Pharmacol. 65: 761-769 [Abstract] [Full Text]  
  • Pascual-Le Tallec, L., Kirsh, O., Lecomte, M.-C., Viengchareun, S., Zennaro, M.-C., Dejean, A., Lombes, M. (2003). Protein Inhibitor of Activated Signal Transducer and Activator of Transcription 1 Interacts with the N-Terminal Domain of Mineralocorticoid Receptor and Represses Its Transcriptional Activity: Implication of Small Ubiquitin-Related Modifier 1 Modification. Mol. Endocrinol. 17: 2529-2542 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitagawa, H.
Right arrow Articles by Kato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitagawa, H.
Right arrow Articles by Kato, S.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»